Summary
DexCom, Inc. (DXCM) reported a strong fiscal year 2025, with revenue reaching $4.66 billion, a 16% increase year-over-year. This growth was primarily driven by increased sales volume of their continuous glucose monitoring (CGM) systems, particularly the Dexcom G7 and the recently launched G7 15 Day system. The company added approximately 600,000-700,000 net customers in 2025. Despite increased sales, gross profit margin saw a slight decrease due to supply availability inefficiencies and build configuration impacts. However, operating income grew significantly by 52%, reaching $911.8 million, supported by controlled operating expenses and a substantial increase in other income. Net income also saw robust growth, up 45% to $836.3 million. The company ended the year with a strong liquidity position, holding $2.00 billion in cash, cash equivalents, and marketable securities, demonstrating effective financial management amidst product innovation and market expansion. The company continues to focus on product development and market expansion, with the recent launch of the Stelo biosensor for prediabetes and Type 2 diabetes patients who do not use insulin marking a strategic move to broaden their market reach. Dexcom is also actively managing regulatory landscapes, addressing an FDA warning letter received in March 2025 regarding manufacturing process non-conformities, and has submitted responses. The company is well-positioned for continued growth, driven by its innovative product pipeline and expanding global presence, though it faces ongoing competitive pressures and evolving reimbursement policies.
Financial Highlights
49 data points| Revenue | $4.66B |
| Cost of Revenue | $1.86B |
| Gross Profit | $2.80B |
| R&D Expenses | $599.10M |
| SG&A Expenses | $1.29B |
| Operating Expenses | $1.89B |
| Operating Income | $911.80M |
| Interest Expense | $14.30M |
| Net Income | $836.30M |
| EPS (Basic) | $2.14 |
| EPS (Diluted) | $2.09 |
| Shares Outstanding (Basic) | 390.20M |
| Shares Outstanding (Diluted) | 405.50M |
Key Highlights
- 1Revenue grew 16% to $4.66 billion in fiscal year 2025, driven by increased customer adoption and sales volume of CGM systems.
- 2Operating income saw substantial growth of 52% to $911.8 million, indicating improved operational efficiency.
- 3Net income increased by 45% to $836.3 million, reflecting strong profitability.
- 4The company ended fiscal 2025 with $2.00 billion in cash, cash equivalents, and marketable securities, showcasing a healthy liquidity position.
- 5Dexcom launched the Stelo biosensor in August 2024, expanding its market to adults with prediabetes and Type 2 diabetes who do not use insulin.
- 6The Dexcom G7 15 Day system received FDA marketing authorization in April 2025, extending wear time and offering improved accuracy.
- 7The company is actively addressing an FDA warning letter from March 2025 concerning manufacturing process non-conformities.